CN106176770A - A kind of male's period of development injecting narcotic - Google Patents
A kind of male's period of development injecting narcotic Download PDFInfo
- Publication number
- CN106176770A CN106176770A CN201610539812.2A CN201610539812A CN106176770A CN 106176770 A CN106176770 A CN 106176770A CN 201610539812 A CN201610539812 A CN 201610539812A CN 106176770 A CN106176770 A CN 106176770A
- Authority
- CN
- China
- Prior art keywords
- component
- male
- development
- period
- injecting narcotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of male's period of development injecting narcotic, comprising: component A:
Description
Technical field
The present invention relates to a kind of male's period of development injecting narcotic.
Background technology
Anesthetics is requisite medicine in medical surgery, is generally divided into general anesthetic and local anesthetic, and complete
Body anesthetics deeply suppresses cerebral cortex, makes people's mind disappear.Tradition use general anesthetic by ether and fluorochemical,
But such medicine storage request is higher, and photodissociation, pyrolysis, poor stability easily occur, and deposits and there is impurity the most at once, impact anesthesia effect
Really, when using especially for male's period of development, being easily caused auximone disorderly, impact is grown.Therefore in the urgent need to exploitation one
Plant the stable anesthetis of safe handling.
Summary of the invention
It is an object of the invention to provide one and deposit stable, free from admixture produces, use safe efficient, have no side effect
Male's period of development injecting narcotic.
The technical scheme is that a kind of male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
Described component A:B:C:D:E mass ratio=1.5:0.8:3:18:2.
Use this compound to prepare anesthetics, can avoid producing, store, transport in decompose and produce impurity, to the period of development
Male without impact, improve safety in utilization.
Detailed description of the invention
A kind of male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
Described component A:B:C:D:E mass ratio=1.5:0.8:3:18:2.
Claims (2)
1. male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
A kind of male's period of development injecting narcotic the most according to claim 1, is characterized in that: described component A:B:C:D:E
Mass ratio=1.5:0.8:3:18:2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610539812.2A CN106176770A (en) | 2016-07-11 | 2016-07-11 | A kind of male's period of development injecting narcotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610539812.2A CN106176770A (en) | 2016-07-11 | 2016-07-11 | A kind of male's period of development injecting narcotic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176770A true CN106176770A (en) | 2016-12-07 |
Family
ID=57473693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610539812.2A Pending CN106176770A (en) | 2016-07-11 | 2016-07-11 | A kind of male's period of development injecting narcotic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176770A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101765582A (en) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | Deuterium-labelled ketamine |
| CN101896205A (en) * | 2007-08-27 | 2010-11-24 | 惠氏有限责任公司 | Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect |
| US8128906B2 (en) * | 2003-10-08 | 2012-03-06 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
-
2016
- 2016-07-11 CN CN201610539812.2A patent/CN106176770A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128906B2 (en) * | 2003-10-08 | 2012-03-06 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| CN101765582A (en) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | Deuterium-labelled ketamine |
| CN101896205A (en) * | 2007-08-27 | 2010-11-24 | 惠氏有限责任公司 | Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017265011B2 (en) | Methods of administering high concentrations of nitric oxide | |
| NZ732507A (en) | Improved compositions for treating muscular dystrophy | |
| RU2013156378A (en) | 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for use in the treatment of adenocystic carcinoma | |
| NZ627274A (en) | Anesthetic compounds and related methods of use | |
| MX347544B (en) | Polycyclic lpa1 antagonist and uses thereof. | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2016008725A (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin. | |
| MX2015012536A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients. | |
| EA201490538A1 (en) | TREATMENT FOR COUGH AND HIS ATTRACTIONS | |
| MX2022003486A (en) | Therapeutic acid ceramidase compositions and methods of making and using them. | |
| NZ630346A (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| RU2015147555A (en) | COMPOUNDS MODIFICATING TELOMERS BY TELOMERASE | |
| CN106176770A (en) | A kind of male's period of development injecting narcotic | |
| JOP20190019A1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN | |
| CN106109468A (en) | A kind of women period of development injecting narcotic | |
| MX2015011624A (en) | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles. | |
| CN106176762A (en) | A kind of local anesthesia anesthetis | |
| MX2021001845A (en) | A combination medicament comprising phenylephrine and paracetamol. | |
| CN106166159A (en) | A kind of compound injection anesthetis | |
| CN106187850A (en) | One can be used as narcotic compound | |
| CN106176746A (en) | A kind of child's injecting narcotic | |
| MX2022000294A (en) | Stable oral composition of cyclophosphamide. | |
| RU2018114922A (en) | TREATMENT OF Focal Alopecia | |
| PH12015502435B1 (en) | Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |